BRPI0715073A8 - métodos e composições para inibir a angiogênese - Google Patents

métodos e composições para inibir a angiogênese

Info

Publication number
BRPI0715073A8
BRPI0715073A8 BRPI0715073A BRPI0715073A BRPI0715073A8 BR PI0715073 A8 BRPI0715073 A8 BR PI0715073A8 BR PI0715073 A BRPI0715073 A BR PI0715073A BR PI0715073 A BRPI0715073 A BR PI0715073A BR PI0715073 A8 BRPI0715073 A8 BR PI0715073A8
Authority
BR
Brazil
Prior art keywords
inhibiting angiogenesis
compositions
methods
biological system
angiogenesis
Prior art date
Application number
BRPI0715073A
Other languages
English (en)
Inventor
Michael Wayte Kenneth
John Story Michael
Original Assignee
Oncology Res International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006904195A external-priority patent/AU2006904195A0/en
Application filed by Oncology Res International Limited filed Critical Oncology Res International Limited
Publication of BRPI0715073A2 publication Critical patent/BRPI0715073A2/pt
Publication of BRPI0715073A8 publication Critical patent/BRPI0715073A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método e composições para inibição da angiogênese. a presente invenção está relacionada a um método de inibição de angiogênese em um sistema biológico. o método inclui a administração ao sistema biológico de uma quantidade eficaz de uma saponina esteroidal.
BRPI0715073A 2006-08-03 2007-08-03 métodos e composições para inibir a angiogênese BRPI0715073A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2006904195A AU2006904195A0 (en) 2006-08-03 Methods and compositions for inhibiting angiogenesis
AU2006904195 2006-08-03
PCT/AU2007/001092 WO2008014564A1 (en) 2006-08-03 2007-08-03 Methods and compositions for inhibiting angiogenesis

Publications (2)

Publication Number Publication Date
BRPI0715073A2 BRPI0715073A2 (pt) 2013-05-28
BRPI0715073A8 true BRPI0715073A8 (pt) 2018-04-10

Family

ID=38996792

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715073A BRPI0715073A8 (pt) 2006-08-03 2007-08-03 métodos e composições para inibir a angiogênese

Country Status (12)

Country Link
US (2) US20090263349A1 (pt)
EP (1) EP2049122B1 (pt)
JP (2) JP5714816B2 (pt)
CN (1) CN101511369B (pt)
AU (1) AU2007281038B2 (pt)
BR (1) BRPI0715073A8 (pt)
CA (1) CA2659542C (pt)
EA (1) EA016653B1 (pt)
ES (1) ES2523463T3 (pt)
MX (1) MX2009001167A (pt)
TW (1) TWI421083B (pt)
WO (1) WO2008014564A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2659537C (en) * 2006-08-03 2016-02-16 Oncology Research International Limited Methods and compositions for promoting activity of anti-cancer therapies
US8507441B2 (en) 2009-10-22 2013-08-13 University of Pittsburgh—Of the Commonwealth Systems of Higher Education Use of endostatin peptides for the treatment of fibrosis
EP2564054A1 (en) 2010-04-30 2013-03-06 Clean Current Limited Partnership Unidirectional hydro turbine with enhanced duct, blades and generator
US20120058088A1 (en) * 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
CN102631616B (zh) * 2012-04-02 2013-05-08 吕明忠 一种治疗风寒型结肠炎的中药制备方法
CN102786594A (zh) * 2012-05-09 2012-11-21 中国药科大学 一种菝葜皂苷元单克隆抗体及其应用
CN104324038B (zh) * 2013-07-24 2018-11-06 四川京华创生物科技有限公司 一种薯蓣皂苷元-3-位衍生物的用途
US20160324884A1 (en) * 2013-11-28 2016-11-10 Xueyong WANG Treatment of diabetes with pentacyclic triterpenoid saponin compounds from szechuan melandium root
CN105640969A (zh) * 2014-11-10 2016-06-08 江苏省中国科学院植物研究所 毛冬青次皂苷的抗菌用途
CN106727611A (zh) * 2015-11-25 2017-05-31 成都易目博科技有限公司 用于预防和治疗血管性疾病的化合物及其制剂
US10925887B2 (en) 2017-02-10 2021-02-23 Oncology Research International Limited Steroid saponins with anti-cancer activity
BR102017016550A2 (pt) * 2017-08-01 2019-03-19 Lisis Rojo Gomes Uso de glicosídeos esteroidais, formulações farmacêuticas, uso de extratos da planta furcraea foetida, processo de obtenção de extratos da planta furcraea foetida e método de tratamento de distúrbios da pele
CN109575102A (zh) * 2018-09-08 2019-04-05 江西中医药大学 延龄草甾体总皂苷及其中甾体皂苷类化合物在制备治疗溃疡性结肠炎药物中的应用
CN110420181A (zh) * 2019-07-24 2019-11-08 西北农林科技大学 一种含有维生素a的纳米乳药物及其制备方法
CN110327354B (zh) * 2019-08-12 2023-08-22 北京市中医研究所 薯蓣皂苷元在银屑病治疗和预防中的应用
CN112194704B (zh) * 2020-10-21 2021-06-01 中国人民解放军空军军医大学 一种甾体皂苷类化合物及其制备方法和应用
CN113181192B (zh) * 2021-04-16 2023-11-07 陕西中医药大学 偏诺皂苷类化合物的应用
WO2024024395A1 (ja) * 2022-07-29 2024-02-01 国立大学法人富山大学 視神経障害の予防または治療のための医薬または飲食品組成物
CN115569144A (zh) * 2022-10-12 2023-01-06 浙江百越生物技术有限公司 纤细薯蓣皂苷在制备预防炎症性肠病药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3123745B2 (ja) 1990-03-16 2001-01-15 三和生薬株式会社 制癌剤
JPH0840914A (ja) 1994-07-29 1996-02-13 Toray Ind Inc 腫瘍細胞増殖阻害剤
KR0164266B1 (ko) * 1996-02-22 1999-01-15 오오니시 쿠니히로 인삼사포닌 장내세균 대사물 및 이를 유효성분으로하는 제암제제
US6261565B1 (en) * 1996-03-13 2001-07-17 Archer Daniels Midland Company Method of preparing and using isoflavones
US20030040463A1 (en) * 1996-04-05 2003-02-27 Wiegand Stanley J. TIE-2 ligands, methods of making and uses thereof
US5985330A (en) * 1996-08-05 1999-11-16 Coastside Bio Resources Inhibition of angiogenesis by sea cucumber fractions
AU761879B2 (en) * 1998-05-19 2003-06-12 Research Development Foundation Triterpene compositions and methods for use thereof
CN1237583A (zh) * 1998-06-01 1999-12-08 沈阳药科大学 一种治疗癌症的甾体皂甙类化合物及其制备方法
US6168795B1 (en) * 1998-06-09 2001-01-02 Sant{acute over (e)} International Inc. Method for anticancer therapy using an herbal extract composition
CA2335436A1 (en) * 2000-02-29 2001-08-29 Glycodesign Inc. Novel core 2 beta-1,6-n-acetylglycosaminyl transferase gene
EP1438059A4 (en) * 2001-10-26 2008-01-23 Angiolab Inc COMPOSITION CONTAINING EXTRACT OF BROWN FROM INDIA PREPARED FOR ANTI-ANGIOGENIC ACTIVITY AND INHIBITOR OF MATRIX METALLOPROTEINASE
US7112573B2 (en) * 2002-04-19 2006-09-26 Iowa Research, The University Foundation Isoflavone and triterpene glycosides from soybeans
US20050143463A1 (en) * 2002-05-03 2005-06-30 The Queen Elizabeth Hospital Research Foundation Inc. Method of inhibiting angiogenesis
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
WO2005072528A1 (en) * 2004-01-27 2005-08-11 Northwestern University Anticancer glycoside compounds
KR100547253B1 (ko) * 2004-05-29 2006-01-26 박명환 암 예방 및 치료에 유효한 진세노사이드 유도체
WO2006053184A2 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing a vascular disease

Also Published As

Publication number Publication date
US20090263349A1 (en) 2009-10-22
CN101511369B (zh) 2012-06-06
CN101511369A (zh) 2009-08-19
CA2659542C (en) 2015-04-07
JP2010500287A (ja) 2010-01-07
JP2013241427A (ja) 2013-12-05
EP2049122A1 (en) 2009-04-22
JP5714816B2 (ja) 2015-05-07
ES2523463T3 (es) 2014-11-26
MX2009001167A (es) 2009-03-20
AU2007281038A1 (en) 2008-02-07
BRPI0715073A2 (pt) 2013-05-28
CA2659542A1 (en) 2008-02-07
EP2049122A4 (en) 2011-05-18
EA016653B1 (ru) 2012-06-29
WO2008014564A1 (en) 2008-02-07
TWI421083B (zh) 2014-01-01
US20150079029A1 (en) 2015-03-19
AU2007281038B2 (en) 2012-11-15
EP2049122B1 (en) 2014-10-08
TW200932245A (en) 2009-08-01
EA200970175A1 (ru) 2009-08-28

Similar Documents

Publication Publication Date Title
BRPI0715073A8 (pt) métodos e composições para inibir a angiogênese
PH12015502136A1 (en) Compositions and methods for treating non-alcoholic steatohepatitis
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
BRPI0800991A2 (pt) composiÇÕes para uso no escurecimento da pele
BRPI0609393B8 (pt) usos de um composto 11-desóxi-prostaglandina
MY158504A (en) Fatty acid niacin conjugates and their uses
PH12013501319A1 (en) Fatty acid acetylated salicylates and their uses
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
CL2007003743A1 (es) Composicion que comprende fenamidona y un compuesto insecticida; y metodo para controlar de forma curativa o preventiva hongos fitopatogenos de cultivos e insectos.
CL2008000022A1 (es) Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer.
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112015023520A2 (pt) purificação do conjugado de anticorpo-fármaco (adc)
AP2518A (en) Processes for production of hoodia plant extracts containing steroidal glycosides
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
WO2011103175A3 (en) Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling
WO2007111992A3 (en) Methods and compositions for treating hypercholesterolemia and atherosclerosis
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
BR112014015354A2 (pt) composição de extratos enriquecidos com elagitaninos no bem-estar sexual
FR2899104B1 (fr) Composition cosmetique au moins un hydroxy acide, au moins un mono ou disaccharide et au moins un ceramide et procedes
SV2009002862A (es) Composiciones de suplementos de hierro de tolerancia mejorada
BR112013000779A2 (pt) composições farmacêuticas de combinação, métodos de tratamento de paciente e uso de forma potencializada ativada de anticorpo para receptor at1 de angiotensina ii e forma potencializada ativada de anticorpo para sintase no endotelial
BRPI0819931A2 (pt) Composições tópicas que compreendem aminoácidos não-proteogênicos e métodos de tratamento de pele
EP2139506A4 (en) COMPOSITION BASED ON REHMANNIAE RADIX PREPARATA, NOTOGINSENG RADIX, OR CERTAIN EXTRACTS AND MIXTURES, FOR THE PREVENTION AND TREATMENT OF PERIODONTITIS

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2473 DE 29-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.